Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999-2018

Connor Griffin1, Uchenna Agbim2, Azaan Ramani1

  • 1Baylor University Medical Center, Dallas, Texas.

Insights

Cirrhosis mortality may be underestimated, particularly in older adults. This study examined liver-related deaths using an updated definition, revealing disproportionate impacts on the elderly population.

Area of Science:

  • Hepatology
  • Geriatric Medicine
  • Public Health

Background:

  • The increasing burden of cirrhosis, especially in the elderly population, is a growing public health concern.
  • An updated definition of cirrhosis demonstrates high accuracy (>90% PPV) in identifying the condition and its complications.
  • Existing data may underestimate cirrhosis-related mortality, with a potential disproportionate impact on older individuals.

Purpose of the Study:

  • To investigate trends in liver-related mortality among the elderly using an updated definition of cirrhosis.
  • To identify demographic and geographic disparities in cirrhosis-related mortality within the elderly population, including gender, race, and rurality.

Main Methods:

  • Utilized an updated definition of cirrhosis with high positive predictive value.
  • Analyzed liver-related mortality trends specifically within the elderly demographic.
  • Examined changes in mortality rates across subsets of gender, race, and rurality.

Main Results:

  • Preliminary analysis suggests cirrhosis-related mortality may be underestimated.
  • The elderly population appears to be disproportionately affected by cirrhosis-related mortality.
  • Trends varied across gender, race, and rurality, indicating specific vulnerable subgroups within the elderly.

Conclusions:

  • Cirrhosis-related mortality, particularly in the elderly, warrants further investigation due to potential underestimation.
  • The updated cirrhosis definition provides a more accurate tool for assessing mortality burden.
  • Targeted public health interventions may be necessary to address disparities in cirrhosis mortality among elderly populations based on demographic and geographic factors.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
22
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
22
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
27
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
25
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
29
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
304